- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06803823
En studie av ONO-2020 hos patienter med agitation associerad med Alzheimers sjukdom demens
En fas 2A, multicenter, placebokontrollerad, randomiserad, dubbelblind, parallellgruppstudie för att utvärdera effektiviteten och säkerheten för ONO-2020 hos patienter med agitation associerad med Alzheimers sjukdomsdemens
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: North America Clinical Trial Support Desk
- Telefonnummer: +18665877745(Toll-Free)
- E-post: clinical_trial@ono-pharma.com
Studera Kontakt Backup
- Namn: International Clinical Trial Support Desk
- Telefonnummer: +17162141777(Standard)
- E-post: clinical_trial@ono-pharma.com
Studieorter
-
-
-
Aichi, Japan
- Rekrytering
- Hotei Hospital
-
Akita, Japan
- Rekrytering
- Akita Prefectural Center For Rehabilitation and Psychiatric Medicine
-
Akita, Japan
- Rekrytering
- Medical Corporation Keishinkai Kyowa Hospital
-
Aomori, Japan
- Rekrytering
- Aiseikai General Incorporated Foundation, Hirosaki Aiseikai Hospital
-
Aomori, Japan
- Rekrytering
- Seinan Hospital
-
Fukui, Japan
- Rekrytering
- Fukui Hospital
-
Fukui, Japan
- Rekrytering
- Matsubara Hospital
-
Fukuoka, Japan
- Rekrytering
- Kuramitsu Hospital
-
Fukuoka, Japan
- Rekrytering
- Aburayama Hospital
-
Gunma, Japan
- Rekrytering
- Kishikai Kishi Hospital
-
Hiroshima, Japan
- Rekrytering
- Hayakawa Clinic
-
Hiroshima, Japan
- Rekrytering
- Koseikai Cocoro Hospital Kusatsu
-
Hiroshima, Japan
- Rekrytering
- Nakamura Hospital
-
Hokkaido, Japan
- Rekrytering
- Keiseikai Hospital
-
Hokkaido, Japan
- Rekrytering
- NHO Obihiro National Hospital
-
Kagoshima, Japan
- Rekrytering
- Ishiki Hospital
-
Kagoshima, Japan
- Rekrytering
- Airanomori Hospital
-
Kagoshima, Japan
- Rekrytering
- Sansyu Hospital
-
Kagoshima, Japan
- Rekrytering
- Taniyama Hospital
-
Kanagawa, Japan
- Rekrytering
- Hatano Kousei Hospital
-
Kanagawa, Japan
- Rekrytering
- Fujisawahospital
-
Kanagawa, Japan
- Rekrytering
- Showa Medical University Northern Yokohama Hospital
-
Kochi, Japan
- Rekrytering
- Hosogi Hospital
-
Kochi, Japan
- Avslutad
- Ichiyo Mental Hospital
-
Kyoto, Japan
- Rekrytering
- Maizuru Medical Center
-
Kyoto, Japan
- Rekrytering
- Nishiyama Hospital
-
Miyagi, Japan
- Rekrytering
- Iryohojin Shadan Shoshinkai Morinohosupitaru・Aoba
-
Nagano, Japan
- Rekrytering
- JA-Nagano North Alps Medical Center Azumi Hospital
-
Nagano, Japan
- Rekrytering
- Jizenkai Ando Hospital
-
Nara, Japan
- Rekrytering
- Nara Medical University Hospital
-
Osaka, Japan
- Rekrytering
- Nagaokai Neyagawa Sanatorium
-
Osaka, Japan
- Rekrytering
- Osaka Institute of Clinical Psychiatry Shin-Abuyama Hospital
-
Osaka, Japan
- Rekrytering
- Osaka Psychiatric Medical Center
-
Saga, Japan
- Rekrytering
- Hizen Psychiatric Center
-
Saga, Japan
- Rekrytering
- Rainbow & Sea Hospital
-
Saitama, Japan
- Rekrytering
- Saitama Konan Hospital
-
Tokyo, Japan
- Avslutad
- Asuka Hospital
-
Tokyo, Japan
- Avslutad
- Nishigahara Hospital
-
Yamagata, Japan
- Rekrytering
- Sanyokai Sanyo Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Diagnosis of probable AD according to the diagnostic criteria for AD dementia (NIA-AA 2011)
- Mini-Mental State Examination (MMSE) score ≥ 5 to ≤ 22 at the start of the treatment period
- Symptoms of agitation defined by the IPA from at least 14 days before the start of the screening period
- Neuropsychiatric Inventory-Nursing Home version (NPI-NH) Agitation/Aggression domain (NPI-NH-A/A) score ≥ 4 at the start of the treatment period.
- Patients who can participate in the study under hospitalization from 21 days before the start of the treatment period to throughout the treatment period
Exclusion Criteria:
- Diagnosis of dementia not due to AD or any other disorder with memory impairment, such as mixed dementia, vascular dementia, Lewy body dementia, dementia associated with Parkinson's disease, frontotemporal dementia, drug-induced dementia, dementia associated with human immunodeficiency virus (HIV) infection, traumatic brain injury, normal pressure hydrocephalus, or other non-AD dementia
- Any MRI or CT scan of the brain performed after the onset of dementia with findings consistent with clinically relevant CNS disease other than AD, such as vascular changes (eg, cortical cerebral infarction, multiple cerebral infarctions), space-occupying lesions (eg, tumors), or any other major structural brain disease
- Delirium within 30 days before the start of the screening period or a history of delirium
- At risk of suicide according to the Columbia-Suicide Severity Rating Scale (C-SSRS) (answers "yes" to Question 4 or 5 of the suicidal ideation section of the C-SSRS) or any suicide attempt within 6 months before the start of the screening period, or at serious risk of suicide in the opinion of the investigator or subinvestigator
- Prior or current treatment with anti-amyloid beta antibodies
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Two ONO-2020 placebo tablets will be orally administered once daily |
|
Experimentell: Ono-2020
|
ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in CMAI score from baseline
Tidsram: up to week 12
|
To assess agitation symptoms |
up to week 12
|
|
Adverse events
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Body weight
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Body temperature
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Blood pressure
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Pulse rate
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Respiratory rate
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
ECG RR interval
Tidsram: up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG PR interval
Tidsram: up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QRS complex
Tidsram: up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QT interval
Tidsram: up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QTcF
Tidsram: up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
Number of participants with abnormal laboratory tests (hematology)
Tidsram: up to week 12
|
Hematology (PT, RBC count, RBC indices, WBC count, Differential, Hemoglobin, Hematocrit) |
up to week 12
|
|
Number of participants with abnormal laboratory tests (Clinical chemistry)
Tidsram: up to week 12
|
Clinical chemistry (Blood urea nitrogen (BUN), Potassium, Creatinine, Sodium, Glucose (fasting or nonfasting), Calcium, Chloride, Total protein, Albumin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase, Total and direct bilirubin, Lactate dehydrogenase (LDH), Phospholipid, γ-Glutamyl transferase (GGT) |
up to week 12
|
|
Number of participants with abnormal Blood coagulation profile (Activated partial thromboplastin time (APTT), Prothrombin time (PT), International normalized ratio (INR))
Tidsram: up to week 12
|
Blood coagulation (Activated partial thromboplastin time (APTT), Prothrombin time (PT), International normalized ratio (INR)) |
up to week 12
|
|
Number of participants with abnormal Urinalysis
Tidsram: up to week 12
|
Urinalysis (pH, Glucose, Protein, Blood, Ketones) |
up to week 12
|
|
COLUMBIA-SUICIDE SEVERITY RATING SCALE(C-SSRS)
Tidsram: up to week 16
|
To Evaluate the Safety |
up to week 16
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cohen-Mansfield Agitation Inventory (CMAI) score at each visit and change from baseline
Tidsram: up to 12 week
|
To Evaluate the Efficacy The range of CMAI score is 29-203. Higher score means a worse outcome. |
up to 12 week
|
|
Clinical Global Impression-Severity (CGI-S) score at each visit and change from baseline
Tidsram: up to 12 week
|
To Evaluate the Efficacy The range of CGI-S score is 0-7. Higher score means a worse outcome. |
up to 12 week
|
|
Clinical Global Impression-Severity (CGI-S) score at each visit
Tidsram: up to 12 week
|
To Evaluate the Efficacy |
up to 12 week
|
|
Neuropsychiatric Inventory in Nursing Home Version(NPI-NH) score at each visit and change from baseline
Tidsram: up to 12 week
|
To Evaluate the Efficacy The range of NPI-NH score is 0-170. Higher score means a worse outcome. |
up to 12 week
|
|
Mini Mental State Exam(MMSE) score at baseline and Week 12, and change from baseline
Tidsram: up to 12 week
|
To Evaluate the Efficacy The range of MMSE score is 0-30. Higher score means a better outcome. |
up to 12 week
|
|
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)score at baseline and Week 12, and change from baseline
Tidsram: up to 12 week
|
To Evaluate the Efficacy The range of ADCS-ADL score is 0-78. Higher score means a better outcome. |
up to 12 week
|
|
Duration of the investigational medicinal product administration
Tidsram: up to 12 week
|
To Evaluate the Efficacy |
up to 12 week
|
|
Pharmacokinetic assessments
Tidsram: up to 12 week
|
Plasma ONO-2020 concentrations |
up to 12 week
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Project Leader, Ono Pharmaceutical Co., Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- ONO-2020-03
- jRCT2041230153 (Registeridentifierare: Japan Registry of Clinical Trials)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .